Dyadic International/ US26745T1016 /

12/8/2023 5:48:19 PM	Chg. -0.01	Volume	Bid-	Ask-	High	Low
1.67USD	-0.30%	70 Turnover: 116.75	-Bid Size: -	-Ask Size: -	1.67	1.67

Newsfile Corp 4/27 BTV Showcases: Champion Iron Limited, Nouveau Monde Graphite, TD Asset Management, and More

GlobeNewswire 3/15/2022 Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

GlobeNewswire 2/10/2022 Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize An...

GlobeNewswire 2/7/2022 Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

GlobeNewswire 1/20/2022 Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Li...

GlobeNewswire 12/22/2021 Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

GlobeNewswire 12/17/2021 Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of T...

GlobeNewswire 11/10/2021 Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

GlobeNewswire 11/9/2021 Dyadic Appoints Chief Business Officer to Executive Leadership Team

GlobeNewswire 10/27/2021 Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

GlobeNewswire 9/10/2021 Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire 8/19/2021 Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neu...

GlobeNewswire 8/11/2021 Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate ...

GlobeNewswire 8/11/2021 Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate ...

GlobeNewswire 7/27/2021 Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Ai...

GlobeNewswire 6/28/2021 Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Review...

GlobeNewswire 5/26/2021 Dyadic announces development of COVID-19 Vaccine in India

GlobeNewswire 5/3/2021 Dyadic to Present at Upcoming Events

GlobeNewswire 4/22/2021 Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Prote...

GlobeNewswire 3/29/2021 UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Cli...

GlobeNewswire 3/29/2021 CEO’s Presenting on the Emerging Growth Conference on March 31. Register now.

GlobeNewswire 3/23/2021 Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

GlobeNewswire 3/22/2021 Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

GlobeNewswire 3/18/2021 Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

GlobeNewswire 3/9/2021 Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting